Repligen Corp
RGEN151.570USD
-9.530-5.92%
收盘 10/28, 16:00（美东）报价延迟15分钟
8.53B总市值
亏损市盈率 TTM
关于 Repligen Corp 公司
Repligen Corporation 是一家全球生命科学公司，致力于开发和商业化生物加工技术和系统。其重点领域是过滤和流体管理、色谱、过程分析和蛋白质。其过滤产品用于工艺开发和工艺规模（临床和商业）生产。其 XCell ATF 系统用于上游灌注（连续）和 N-1（强化补料分批或混合灌注）细胞培养处理。其色谱特许经营包括用于生物药物下游纯化、开发、制造和质量控制的多种产品。其过程分析产品补充并支持其过滤、色谱和蛋白质特许经营。其 TangenX 产品组合包括主要用于下游和超滤过程的平板 (FS) 切向流过滤 (TFF) 盒。其桌面产品组合包括 MAVERICK 和 MAVEN、REBEL 和 ZipChip。
Repligen Corp简介
公司代码RGEN
公司名称Repligen Corp
上市日期Apr 29, 1986
CEOMr. Olivier Loeillot
员工数量1778
证券类型Ordinary Share
年结日Apr 29
公司地址Building 1, Suite 100
城市WALTHAM
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02453
电话17814499560
网址https://www.repligen.com/
公司代码RGEN
上市日期Apr 29, 1986
CEOMr. Olivier Loeillot
Repligen Corp公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.06K
-8.72%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
13.06K
-8.72%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
暂无数据
地区USD
名称
营收
占比
North America
89.36M
49.00%
Europe
69.30M
38.00%
APAC/Other
23.71M
13.00%
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
其他
67.25%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.00%
BlackRock Institutional Trust Company, N.A.
8.37%
T. Rowe Price Associates, Inc.
6.10%
Roy T. Eddleman UEO
5.89%
Point72 Asset Management, L.P.
3.40%
其他
67.25%
股东类型
持股股东
占比
Investment Advisor
54.39%
Investment Advisor/Hedge Fund
25.75%
Hedge Fund
12.98%
Individual Investor
6.38%
Research Firm
2.41%
Pension Fund
2.37%
Bank and Trust
0.68%
Sovereign Wealth Fund
0.60%
Family Office
0.50%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1008
55.75M
99.10%
-5.55M
2025Q2
1028
61.98M
110.32%
-3.21M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
5.07M
9%
-2.87K
-0.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.71M
8.37%
-180.36K
-3.69%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.43M
6.1%
-3.13M
-47.69%
Aug 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
Point72 Asset Management, L.P.
1.91M
3.4%
+796.75K
+71.36%
Jun 30, 2025
State Street Investment Management (US)
1.62M
2.88%
-66.31K
-3.93%
Jun 30, 2025
Champlain Investment Partners, LLC
1.40M
2.49%
-62.91K
-4.30%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.36M
2.43%
+842.96K
+161.67%
Jun 30, 2025
Sands Capital Management, LLC
1.25M
2.22%
-43.11K
-3.33%
Jun 30, 2025
Invesco Advisers, Inc.
1.25M
2.22%
-348.59K
-21.85%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
First Trust NYSE Arca Biotechnology Index Fund
3.05%
Invesco Biotechnology & Genome ETF
2.57%
Congress SMid Growth ETF
1.97%
iShares Health Innovation Active ETF
1.52%
VanEck Biotech ETF
1.27%
Franklin Genomic Advancements ETF
0.98%
WisdomTree BioRevolution Fund
0.98%
Pacer US Export Leaders ETF
0.87%
iShares Biotechnology ETF
0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
0.5%
查看更多
First Trust NYSE Arca Biotechnology Index Fund
占比3.05%
Invesco Biotechnology & Genome ETF
占比2.57%
Congress SMid Growth ETF
占比1.97%
iShares Health Innovation Active ETF
占比1.52%
VanEck Biotech ETF
占比1.27%
Franklin Genomic Advancements ETF
占比0.98%
WisdomTree BioRevolution Fund
占比0.98%
Pacer US Export Leaders ETF
占比0.87%
iShares Biotechnology ETF
占比0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.5%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
